Lu Xianping orphan drug localization is one of the fundamental way to treat rare diseases – Sohu hea-dxperience

Home / Lu Xianping orphan drug localization is one of the fundamental way to treat rare diseases – Sohu hea-dxperience

Lu Xianping: "the localization of orphan drug treatment is one of the fundamental way – a rare disease by Sohu health rare disease development center (CORD), jointly organized by the fifth session of Chinese Epidendrum medical rare disease forum will be held September 22, 2016 -24, held in Hangzhou Shangri-La Hotel. By then, we will work with stakeholders to discuss how China’s rare disease work more efficiently and effectively. The conference will be invited to Mr. Lu Xianping, the founder of Shenzhen Chipscreen director, President and chief scientific officer of the company, as a conference speaker. He will introduce the company’s first successful research and development and in accordance with the approval of orphan drug market research and development experience. Guest: Lu Xianping, President and chief scientific officer of Shenzhen Chipscreen director, founder of the company, the conference theme first according to the direction of orphan drug approved drug chidamide development and challenge China Q: as an expert, familiar with the pharmaceutical market situation Chinese at present, in the field of orphan drugs, China orphan drug market. Whether it is to meet the degree from the profit space of development or rare disease patients demand is far insufficient, you think one of the biggest problems where? Answer: the main body of new drug research and development is the enterprise of new drug research and development. The definition of many kinds of rare diseases, patients with a relatively small market, small (according to the indications for classification); basic research and rare diseases is also less developed is more difficult; if considering from the needs of patients, drug companies spend much energy (money, time and cost) to develop, according to the indications approved, according to new drug pricing the market returns are unlikely to support the continued development and long-term development of enterprises. Such R & D investment and market return mismatch caused by the difficulties of survival and development of enterprises is the main problem. Therefore, in a market economy system to improve the supply of orphan drugs, the government needs to develop stimulus is particularly important. As early as 1983, the United States formulated the "Orphan Drug Act", FDA "in order to reduce the number, quantity, speed up the approval of clinical clinical free" and other preferential policies, greatly promoted the development of orphan drugs, the American Pharmaceutical Company data show that in 1973 to 1983 ten years, only 10 U.S. orphan drug market in 1983; the "Orphan Drug Act" was enacted, there are nearly 500 orphan drugs listed from 1983 to 2015. Japan implemented the "orphan drug management system" in 1993, the whole process can enjoy the fund subsidy, tax cuts, priority approval, and then review the drug time and preferential policies of national health insurance payment on the use of rare diseases. So far, at least more than and 40 countries and regions in the world passed the orphan drug act. Thanks to price management, Fund grants, tax breaks, as well as market exclusivity and other preferential policies, foreign orphan drug research and development in full swing. But, in Chinese, by lack of special and incentive policies for rare disease drugs, there is no national security policy for rare disease treatment costs, the domestic pharmaceutical companies to ‘orphan drugs’ R & D power was insufficient, the orphan drug’s original research enterprise is scanty, coupled with foreign orphans.相关的主题文章: